Skip to content
10-Q

Quarterly Report

NEXUS BIOPHARMA INC

0001078782-17-000445

← back to feed
Filed
Apr 10, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2017 · Apr 6, 2017 64.3M sh
Cash And Equivalents Q3 2017 · Nov 30, 2016 $302
Cash And Equivalents Q3 2017 · Feb 29, 2016 $9.93K
Cash And Equivalents Q3 2017 · Feb 28, 2015 $22.05K
Current Liabilities Q3 2017 · Nov 30, 2016 $1.32M
Current Liabilities Q3 2017 · Feb 29, 2016 $735.61K
Total Liabilities Q3 2017 · Nov 30, 2016 $1.36M
Total Liabilities Q3 2017 · Feb 29, 2016 $776.72K
Current Assets Q3 2017 · Nov 30, 2016 $9.29K
Current Assets Q3 2017 · Feb 29, 2016 $9.93K
Total Assets Q3 2017 · Nov 30, 2016 $18.25K
Total Assets Q3 2017 · Feb 29, 2016 $9.93K
Sga Expense Q3 2017 · Nov 30, 2016 $121.46K
Sga Expense Q3 2017 · Nov 30, 2016 $530.88K
Sga Expense Q3 2017 · Nov 30, 2015 $51.25K
Sga Expense Q3 2017 · Nov 30, 2015 $854.52K
Rd Expense Q3 2017 · Nov 30, 2016 $7.5K
Rd Expense Q3 2017 · Nov 30, 2016 $23.9K
Rd Expense Q3 2017 · Nov 30, 2015 $107.94K
Rd Expense Q3 2017 · Nov 30, 2015 $218.84K
Net Income Q3 2017 · Nov 30, 2016 −$137.92K
Net Income Q3 2017 · Nov 30, 2016 −$576.91K
Net Income Q3 2017 · Nov 30, 2015 −$159.18K
Net Income Q3 2017 · Nov 30, 2015 −$1.07M